Advances in mesenchymal stem cell transplantation for the treatment of osteoporosis

Cell Proliferation
Yuhe JiangYongsheng Zhou

Abstract

Osteoporosis is a systemic metabolic bone disease with characteristics of bone loss and microstructural degeneration. The personal and societal costs of osteoporosis are increasing year by year as the ageing of population, posing challenges to public health care. Homing disorders, impaired capability of osteogenic differentiation, senescence of mesenchymal stem cells (MSCs), an imbalanced microenvironment, and disordered immunoregulation play important roles during the pathogenesis of osteoporosis. The MSC transplantation promises to increase osteoblast differentiation and block osteoclast activation, and to rebalance bone formation and resorption. Preclinical investigations on MSC transplantation in the osteoporosis treatment provide evidences of enhancing osteogenic differentiation, increasing bone mineral density, and halting the deterioration of osteoporosis. Meanwhile, the latest techniques, such as gene modification, targeted modification and co-transplantation, are promising approaches to enhance the therapeutic effect and efficacy of MSCs. In addition, clinical trials of MSC therapy to treat osteoporosis are underway, which will fill the gap of clinical data. Although MSCs tend to be effective to treat osteoporosis, the...Continue Reading

References

Nov 1, 1994·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·J A Kanis
Apr 5, 1996·Science·E C Butcher, L J Picker
Jun 27, 2002·Proceedings of the National Academy of Sciences of the United States of America·Edwin M HorwitzTed Hofmann
Apr 30, 2003·Proceedings of the National Academy of Sciences of the United States of America·Masako MiuraSongtao Shi
Mar 6, 2004·The Journal of Clinical Endocrinology and Metabolism·Ki Hyun BaekChoon Choo Kim
Mar 24, 2005·Journal of Cellular Biochemistry·Toshihisa Komori
Jun 1, 2005·The Journal of Gene Medicine·Hajime TsudaHirofumi Hamada
Sep 6, 2005·Blood·Anna CorcioneAntonio Uccelli
Nov 8, 2006·The Journal of Experimental Medicine·Kojiro SatoHiroshi Takayanagi
Sep 28, 2007·Nature·Ralph M Steinman, Jacques Banchereau
Dec 1, 2007·Arthritis and Rheumatism·Mario M ZaissGeorg Schett
Mar 15, 2008·Biochemical and Biophysical Research Communications·Yan-Min ZhaoHe Huang
May 6, 2008·European Cells & Materials·J M Kanczler, R O C Oreffo
Oct 28, 2008·PloS One·Maria Arantzazu Sanchez-FernandezBernard Hoflack
Jun 26, 2009·Gerodontology·Saumyendra V Singh, Arvind Tripathi
Jul 16, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Sun Wook ChoChan Soo Shin
Oct 31, 2009·Arthritis and Rheumatism·Luca Dalle CarbonareVincenzo Lo Cascio
Jan 14, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Sanjay KumarSelvarangan Ponnazhagan
Feb 20, 2010·Arthritis Research & Therapy·Iannis E AdamopoulosEdward P Bowman
Apr 9, 2010·Connective Tissue Research·Natália de Melo OcarinoRogéria Serakides
May 7, 2010·Journal of Cell Science·Vandhana Muralidharan-ChariCrislyn D'Souza-Schorey
Aug 13, 2010·Kidney International·Giovanni CamussiLuigi Biancone
Aug 18, 2010·Oral and Maxillofacial Surgery Clinics of North America·Amjad JavedFarah Y Ghori
Oct 13, 2010·Annual Review of Pathology·Xu Feng, Jay M McDonald

❮ Previous
Next ❯

Citations

Aug 24, 2021·Frontiers in Endocrinology·Shu-Ting LinSi-Qing Cai

❮ Previous
Next ❯

Methods Mentioned

BETA
gene modification
gene knockout

Clinical Trials Mentioned

NCT02566655
NCT01532076
NCT02008539
NCT02530047
NCT02068794
NCT01983709

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.